May 21, 2021
BeiGene Announces Positive Topline Results from Phase 3 Trial of Tislelizumab in Combination with Chemotherapy as First-Line Treatment for Recurrent or Metastatic Nasopharyngeal Cancer    read more...
May 19, 2021
BeiGene to Showcase Broad Clinical Portfolio at 2021 ASCO Annual Meeting    read more...
May 19, 2021
BeiGene Announces U.S. FDA Acceptance and Priority Review of Supplemental New Drug Application for BRUKINSA® (Zanubrutinib) in Marginal Zone Lymphoma    read more...
May 12, 2021
BeiGene Highlights Progress in Hematology at EHA2021 Virtual Congress    read more...
May 07, 2021
China NMPA Approves PARP Inhibitor Pamiparib for Patients with Previously Treated Advanced Ovarian Cancer    read more...
May 06, 2021
BeiGene Reports First Quarter 2021 Financial Results    read more...
Apr 28, 2021
BRUKINSA® (Zanubrutinib) Demonstrates Superior Objective Response Rate by Investigator Assessment and Reduced Rates of Atrial Fibrillation or Flutter at Interim Analysis in Head-to-Head Trial Against Ibrutinib in Chronic Lymphocytic Leukemia    read more...
Apr 21, 2021
BeiGene Announces Acceptance of a Supplemental New Drug Application for Tislelizumab in Combination with Chemotherapy in First-Line Advanced Squamous NonSmall Cell Lung Cancer in China    read more...
Apr 12, 2021
BeiGene Presents Interim Analysis Results of RATIONALE 303 Trial of Tislelizumab in Second- or Third-Line Non-Small Cell Lung Cancer at the AACR Annual Meeting 2021    read more...
Apr 11, 2021
BeiGene Presents Clinical Data on Sitravatinib in Combination with Tislelizumab at the AACR Annual Meeting 2021    read more...
Apr 08, 2021
BeiGene Provides Update on Phase 2 Clinical Trial of Zanubrutinib in Patients with COVID-19-Related Pulmonary Distress    read more...
Apr 08, 2021
BeiGene Launches BRUKINSA® (Zanubrutinib) in Canada for Patients with Waldenström’s Macroglobulinemia    read more...
Apr 07, 2021
BeiGene Announces First Commercial Manufacturing Approval for Its State-of-the-Art Biologics Facility in Guangzhou, China    read more...
Mar 30, 2021
BeiGene Announces New Chief Financial Officer, Julia Wang    read more...
Mar 10, 2021
BeiGene Announces Presentation of Clinical and Preclinical Data at the AACR Annual Meeting 2021    read more...
Mar 10, 2021
BeiGene Initiates Phase 1 Clinical Trial for HPK1 Inhibitor BGB-15025    read more...
Mar 05, 2021
BeiGene Announces Acceptance of a Supplemental Biologics License Application in China for Tislelizumab in Second- or Third-line Non-Small Cell Lung Cancer    read more...
Mar 02, 2021
Health Canada Approves BRUKINSA® (Zanubrutinib) for the Treatment of Waldenström’s Macroglobulinemia    read more...
Feb 26, 2021
BeiGene Announces Closing of Collaboration with Novartis to Develop and Commercialize Anti-PD-1 Antibody Tislelizumab in North America, Europe and Japan    read more...
Feb 25, 2021
BeiGene Reports Fourth Quarter and Full Year 2020 Financial Results    read more...